ILLUMINA CAMBRIDGE LIMITED
Formerly known as Solexa Limited, the company serves as the UK biotechnology research and experimental development subsidiary of the US-headquartered genomics group Illumina, Inc.
Get an alert when ILLUMINA CAMBRIDGE LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£51M
USD 67,196,000
Latest balance sheet
Net assets
£637M
USD 846,996,000
Equity attributable
Employees
731
Average over period
Profit before tax
£380M
USD 505,706,000
Period ending 2024-12-29
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-29
| Metric | Trend | 2023-12-31 | 2024-12-29 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £2,436,276,780 | £2,338,276,329 | — | |
| Operating profit | £153,790,874 | £82,013,080 | — | |
| Profit before tax | £421,456,814 | £380,144,328 | — | |
| Net profit | £388,201,909 | £315,236,413 | — | |
| Cash | £42,425,017 | £50,511,915 | — | |
| Total assets less current liabilities | £771,092,987 | £707,629,858 | — | |
| Net assets | £741,171,164 | £636,695,482 | — | |
| Equity | £741,171,164 | £636,695,482 | — | |
| Average employees | 823 | 731 | — | |
| Wages | £73,604,450 | £70,690,070 | — | |
| Directors' remuneration | £990,002 | £650,229 | — |
Figures converted to GBP from USD at 0.752 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. Year-on-year comparison hidden: this filing covers about 12 months versus 12 months prior. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-29 |
|---|---|---|---|
| Operating margin | 6.3% | 3.5% | |
| Net margin | 15.9% | 13.5% | |
| Return on capital employed | 19.9% | 11.6% | |
| Gearing (liabilities / total assets) | 25.1% | 38.1% | |
| Current ratio | 3.10x | 2.32x | |
| Interest cover | 15.39x | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- ILLUMINA CAMBRIDGE LIMITED 2008-01-04 → present
- SOLEXA LIMITED 1998-10-09 → 2008-01-04
- INTERCEDE 1356 LIMITED 1998-09-02 → 1998-10-09
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for the period to 31 December 2026.”
Group structure
- ILLUMINA CAMBRIDGE LIMITED · parent
- Illumina India Biotechnology Private Ltd 100%
- Illumina Singapore Pte. Ltd. 100%
- Illumina Canada ULC 100%
- BlueBee Holding B.V. 100%
- Emedgene Technologies Ltd 100%
- Illumina Colombia S.A.S. 100%
- Illumina Mexico Productos de Biotecnologia 99%
- Illumina Uruguay SRL 99%
- Illumina Chile SpA 100%
Significant events
- “In December 2024 Illumina Cambridge opened a branch in Singapore for the purpose of undertaking R&D activity. 30 employees transitioned from Illumina Singapore Pte. Ltd., which is wholly owned by Illumina Cambridge, into the branch. The branch accounts have been incorporated within those of Illumina Cambridge.”
- “On the 28th March 2025 a dividend of $105,000,000 was received from Illumina Singapore Pte. Ltd.”
- “On the 28th March 2025 a dividend of $155,000,000 was paid by Illumina Cambridge to Illumina, Inc.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 36 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ROBINSON, Mark James | Director | 2019-11-04 | Dec 1975 | British |
| SALES, Nicholas Simon | Director | 2025-05-15 | Mar 1975 | British |
Show 36 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ABELL, James Foster | Secretary | 1998-10-12 | 2001-11-20 |
| CABOU, Christian | Secretary | 2007-01-26 | 2013-04-22 |
| DADSWELL, Charles | Secretary | 2013-04-22 | 2024-11-22 |
| DOOGAN, Andrew Kevin | Secretary | 2024-11-22 | 2025-03-07 |
| PALMER, Leigh Graham | Secretary | 2001-11-20 | 2007-01-26 |
| MITRE SECRETARIES LIMITED | Corporate Nominee Secretary | 1998-09-02 | 1998-10-12 |
| ALLEN, Stephen David | Director | 2004-01-27 | 2007-01-26 |
| BALASUBRAMANIAN, Shankar, Dr | Director | 1998-10-12 | 2007-01-26 |
| BERRIMAN, John Edward | Director | 1998-10-12 | 2004-06-08 |
| CARTHY, Mark | Director | 2001-09-20 | 2005-04-19 |
| COMPTON, Richard Alan | Director | 2015-04-29 | 2016-05-03 |
| CRANFIELD, Nicola Letha, Ms. | Director | 2021-12-03 | 2025-05-15 |
| DANIEL, Tom James | Director | 2001-09-20 | 2005-04-19 |
| DESOUZA, Francis | Director | 2015-04-29 | 2017-04-13 |
| DOWDY, Paula Lynn | Director | 2016-10-24 | 2021-07-23 |
| EDWARDS, Rebecca Jane | Director | 2018-10-08 | 2021-11-19 |
| ELETR, Sam, Dr | Director | 2002-01-29 | 2004-07-30 |
| FLATLEY, Jay | Director | 2007-01-26 | 2015-04-29 |
| HAUSER, Hermann Maria | Director | 2004-07-30 | 2005-04-19 |
| HENRY, Christian Ogren | Director | 2007-12-20 | 2017-04-13 |
| JENNINGS, Richard Charles, Dr | Director | 1998-10-12 | 2001-09-20 |
| KLENERMAN, David | Director | 1998-10-12 | 2001-09-20 |
| LLOYD HARRIS, Quentin Lionel Genghis, Dr | Director | 2004-06-08 | 2005-04-19 |
| MCCOOKE, Nicholas John | Director | 2001-01-24 | 2004-08-09 |
| MCGRATH, Ronald James | Director | 2017-04-13 | 2018-01-22 |
| NEL, Andre Jacques | Director | 2015-04-29 | 2019-11-04 |
| ORPIN, Timothy Sean | Director | 2013-03-14 | 2015-04-29 |
| REEVES, Barbara | Nominee Director | 1998-09-02 | 1998-10-12 |
| RICH, Michael William | Nominee Director | 1998-09-02 | 1998-10-12 |
| RINK, Timothy James, Dr | Director | 2000-07-19 | 2007-01-26 |
| SMITH, Anthony John | Director | 2002-01-29 | 2007-01-26 |
| STAPLEY, Marc Andrew | Director | 2012-05-08 | 2015-04-29 |
| VAN OENE, Mark David | Director | 2017-09-14 | 2018-10-08 |
| VERHOEF, Bastiaan Abram Willem | Director | 2023-04-28 | 2024-02-07 |
| WEST, John Stephen | Director | 2004-08-06 | 2007-01-26 |
| WILLIAMSON, Alan Rowe, Dr | Director | 2000-07-19 | 2004-07-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Illumina Inc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors (as firm), Significant influence (as firm) | 2016-04-06 | Active |
Filing timeline
Last 20 of 188 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-18 | AA | accounts | Accounts with accounts type full | |
| 2025-05-19 | AP01 | officers | Appoint person director company with name date | |
| 2025-05-16 | TM01 | officers | Termination director company with name termination date | |
| 2025-05-13 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-11-28 | AP03 | officers | Appoint person secretary company with name date | |
| 2024-11-28 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-09-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-08-31 | AA | accounts | Accounts with accounts type full | |
| 2024-02-07 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-28 | AA | accounts | Accounts with accounts type full | |
| 2023-09-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-05-05 | AP01 | officers | Appoint person director company with name date | |
| 2022-09-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-30 | AA | accounts | Accounts with accounts type full | |
| 2021-12-03 | AP01 | officers | Appoint person director company with name date | |
| 2021-12-01 | TM01 | officers | Termination director company with name termination date | |
| 2021-09-14 | AA | accounts | Accounts with accounts type full | |
| 2021-09-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-07-23 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.